These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 29579035)

  • 41. GLP-1 receptor agonists and heart failure in diabetes.
    Scheen AJ
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S13-2S19. PubMed ID: 28431666
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
    Balakumar P; Dhanaraj SA
    Cell Signal; 2013 Sep; 25(9):1799-803. PubMed ID: 23707531
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2018 Jun; 17(1):85. PubMed ID: 29895290
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus.
    Asleh R; Sheikh-Ahmad M; Briasoulis A; Kushwaha SS
    Heart Fail Rev; 2018 May; 23(3):445-459. PubMed ID: 29270818
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [SGLT2 inhibitor or GLP-1 receptor agonist in a type 2 diabetic patient with cardiovascular disease ?].
    Scheen AJ; Paquot N
    Rev Med Suisse; 2018 Aug; 14(615):1460-1465. PubMed ID: 30136462
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Type 2 diabetes and cardiovascular prevention: the dogmas disputed.
    Giugliano D; Maiorino MI; Bellastella G; Esposito K
    Endocrine; 2018 May; 60(2):224-228. PubMed ID: 28895030
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology.
    Tanaka A; Node K
    J Cardiol; 2017 Mar; 69(3):501-507. PubMed ID: 28043708
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
    Perreault L
    Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever.
    Basile JN
    Hosp Pract (1995); 2016; 44(1):9-20. PubMed ID: 26781810
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of sodium-glucose cotransporter inhibitors on cardiorenal and metabolic systems: Latest perspectives from the outcome trials.
    Lim S
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():5-8. PubMed ID: 31081588
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
    Scheen AJ; Piérard L; Krzesinski JM; Paquot N
    Rev Med Liege; 2016 Sep; 71(9):376-381. PubMed ID: 28383832
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight.
    Coch RW; Green JB
    Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):767-72. PubMed ID: 27378397
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus.
    Blonde L
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S4-11. PubMed ID: 19952303
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Cardiovascular effects of new non-insulinic anti-diabetes drugs].
    Dieuzeide G; Puchulu F; Sanabria H; Sinay I
    Medicina (B Aires); 2018; 78(3):185-193. PubMed ID: 29940545
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus.
    Kaneko M; Narukawa M
    Diabetes Res Clin Pract; 2016 Jun; 116():171-82. PubMed ID: 27321333
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.
    Lau DC; Teoh H
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S148-54. PubMed ID: 26654858
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition.
    Dokken B
    J Cardiovasc Nurs; 2016; 31(3):274-83. PubMed ID: 25829138
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ
    Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiovascular Effects of Incretin-Based Therapies.
    White WB; Baker WL
    Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.